You are viewing an incomplete version of our website. Please click to reload the website as full version.

Activin Receptor Type I (ACRV1) (AA 132-161), (Center) antibody

Details for Product No. ABIN657777, Supplier: Login to see
Antigen
  • ALK2
  • ActR-I
  • ActRIA
  • Acvr
  • Acvrlk2
  • Alk-2
  • Alk8
  • D330013D15Rik
  • SKR1
  • Tsk7L
  • ACTRI
  • ACVR1A
  • ACVRLK2
  • FOP
  • TSRI
  • ActR-IA
Epitope
AA 132-161, Center
59
40
20
15
15
14
12
9
4
4
4
3
3
3
3
2
2
2
2
2
2
1
1
1
1
Reactivity
Human
137
43
12
7
4
2
2
2
1
1
1
1
1
1
1
1
Host
Rabbit
119
23
5
1
Clonality (Clone)
Polyclonal ()
Conjugate
Un-conjugated
13
9
7
7
7
7
Application
Western Blotting (WB)
128
89
62
24
3
3
2
1
Supplier
Login to see
Supplier Product No.
Login to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Available images

Immunogen This ACVR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 132-161 AA from the Central region of human ACVR1.
Clone RB33883
Isotype Ig
Specificity This ACVR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 131-161 amino acids from the Central region of human ACVR1.
Predicted Reactivity Cow (Bovine),Mouse (Murine),Rat (Rattus)
Purification This antibody is purified through a protein A column, followed by peptide affinity purification.
Alternative Name ACVR1 (ACRV1 Antibody Abstract)
Background Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I ( I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. This gene encodes activin A type I receptor which signals a particular transcriptional response in concert with activin type II receptors. Mutations in this gene are associated with fibrodysplasia ossificans progressive.
Synonyms: Activin receptor type-1,ACVR1,ACVRLK2
Molecular Weight 57153 DA
Gene ID 90
NCBI Accession NP_001096, NP_001104537
UniProt Q04771
Research Area Phospho-specific antibodies, Cell Signaling, Cell Structure, Protein Modifications, Chromatin, Signaling
Pathways
Application Notes WB = 1:1000
Restrictions For Research Use only
Format Liquid
Concentration 0.47 mg/mL
Buffer PBS with 0.09 % (W/V) sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C/-20 °C
Storage Comment ACVR1 Antibody (Center) can be refrigerated at 2-8 °C for up to 6 months. For long term storage, place the at -20 °C.
Expiry Date 6 months
Supplier Images
Western Blotting (WB) image for anti-Activin Receptor Type I (ACRV1) (AA 132-161), (Center) antibody (ABIN657777) Western blot analysis of ACVR1 (arrow) using rabbit polyclonal ACVR1 Antibody (Center...
Background publications Shimada, Miyagawa, Kawashima et al.: "An approach based on a genome-wide association study reveals candidate loci for narcolepsy." in: Human genetics, Vol. 128, Issue 4, pp. 433-41, 2010 (PubMed).

Canzian, Cox, Setiawan et al.: "Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium." in: Human molecular genetics, Vol. 19, Issue 19, pp. 3873-84, 2010 (PubMed).

Song, Kim, Woo et al.: "Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva." in: The Journal of biological chemistry, Vol. 285, Issue 29, pp. 22542-53, 2010 (PubMed).

Herrera, van Dinther, Ten Dijke et al.: "Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation." in: Cancer research, Vol. 69, Issue 24, pp. 9254-62, 2009 (PubMed).